Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer

Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer

Thyroid cancer is the most common type of endocrine malignancy. Cornerstones of thyroid cancer treatment include surgery, radioactive iodine ablation, and thyroid stimulating hormone suppression. The National Comprehensive Cancer Network guidelines recommend two tyrosine kinase inhibitors for thyroi...

Full description

Bibliographic Details
Main Authors: Selina K. Wong, Quincy S.C. Chu, Jennifer L. Spratlin, Randeep Sangha, Alexander J.B. McEwan, Donald W. Morrish, Diane Arndt, Gwen Sergenson, Adriaan Cleton, Funan Huang, Michael B. Sawyer
Format: Article
Language:English
Published: Karger Publishers 2019-10-01
Series:Case Reports in Oncology
Subjects:
iodine-refractory
regorafenib
thyroid cancer
Online Access:https://www.karger.com/Article/FullText/503419

Internet

https://www.karger.com/Article/FullText/503419

Similar Items